The Lancet Oncology · 2016 · 676 citations · 29 references
UrologyGenitourinary CancerMedicineCheckmate 032Immune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyMolecular OncologyNivolumab Monotherapy
29
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.3K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas et al. · New England Journal of Medicine · 2015 · 8.4K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.3K citations · Full text